Tag
A secondary analysis of the PROMISE trial reveals that women face elevated cardiovascular risk at significantly lower coronary plaque thresholds than men, necessitating a paradigm shift toward sex-stratified interpretation of coronary CT an
This review analyzes global radiation doses in CAD diagnostic imaging based on the INCAPS 4 study. It highlights significant disparities across modalities and regions, revealing that patients in low-income countries and those undergoing CCT
A substudy of the PROMISE trial demonstrates that quantitative plaque measures on CCTA—specifically total and noncalcified plaque burden—independently predict major adverse cardiovascular events in symptomatic outpatients, offering a precis
The ABILITY Diabetes Global trial demonstrates that the Abluminus DES+ sirolimus-eluting stent failed to meet non-inferiority compared to the XIENCE everolimus-eluting stent in patients with diabetes, showing significantly higher rates of t
The NOTION-3 trial demonstrates that FFR-guided revascularization significantly reduces cardiovascular risks in TAVR patients with coronary artery disease, validating the 0.80 threshold for clinical decision-making.
A post hoc analysis of the SCOPE I trial reveals that obstructive coronary artery disease (CAD) does not significantly impact 3-year survival or patient-reported health status following TAVR, questioning the routine necessity of periprocedu
A multidimensional study of 95 CAD patients shows that RNA-rich reticulated platelets exhibit a distinct prothrombotic transcriptomic and proteomic signature with upregulated GPVI and PI3K signalling; GPVI and PI3K inhibition reduced RP-dri
In a propensity‑matched Ontario cohort of women with chronic severe coronary artery disease, CABG was associated with lower long‑term MACCE and all‑cause mortality than PCI over a median 5.1 years.
A large-scale multi-ancestry genetic study confirms consistent associations between LDL cholesterol levels and coronary artery disease risk across six global ancestries, highlighting the generalizability of LDL-C lowering interventions beyo
This review discusses a landmark study demonstrating how wearable devices and online coaching improve exercise capacity in coronary artery disease patients, highlighting advancements in remote cardiac rehabilitation.
This randomized controlled non-inferiority trial demonstrates that X-CircuiT, a smartphone-guided multi-component exercise regime, is as effective and safe as conventional exercise in improving fitness in home-based cardiac rehabilitation f
This meta-analysis of nearly 29,000 CAD patients shows clopidogrel monotherapy reduces major cardiovascular events more than aspirin without increasing major bleeding risk, supporting clopidogrel as preferred secondary prevention.
This post hoc AFIRE trial analysis shows rivaroxaban monotherapy reduces major cardiovascular events and major bleeding across age groups in AF with stable CAD, with notable age-related efficacy and safety trends warranting further research
The PROMISE trial’s 10-year follow-up shows no difference in all-cause or cardiovascular mortality between initial functional stress testing and anatomic coronary CTA in symptomatic patients with suspected coronary artery disease.
A one-year DASH diet intervention led to sustained suppression of proatherogenic chemokine CXCL4 and fewer major cardiovascular events over six years despite reduced adherence and partial loss of initial benefits in nonobstructive CAD patie
Machine learning models trained on clinical data improve prediction of coronary artery disease on CT scans compared to traditional risk scores, potentially guiding better resource utilization in cardiovascular care.
Discover the causes of organ calcification, differentiate harmless from dangerous types, and learn how to interpret your health reports with expert advice.
A large meta-analysis in The Lancet demonstrates that clopidogrel reduces MACCE risk by 14% over aspirin in CAD secondary prevention, with comparable safety over 5.5 years.
Prasugrel demonstrates a more rapid and significant inhibition of platelet aggregation than clopidogrel in patients with stable coronary artery disease and impaired renal function, particularly within the first week of therapy.
